TransMedics to Present at Upcoming Investor Conferences

ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in three upcoming investor conferences.

PRNewsWire • 2 hours ago

TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026

ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026.

PRNewsWire • Oct 22, 2026

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Sep 26, 2026

TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing Risks

TransMedics is a market-changing player in organ transplant technology, with a unique multi-organ perfusion platform and integrated logistics network. TMDX earns a buy rating as recent pullbacks, driven by margin volatility due to higher investments, present an attractive entry point for long-term investors. Key growth drivers include the upcoming kidney OCS product (potential FDA submission in 2027) and international expansion, targeting $2B+ revenue by 2032.

Seeking Alpha • Sep 26, 2026

TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)

TransMedics' liver growth is moderating, increasing the company's dependence on international markets and heart, lung, and kidney to sustain growth. Heart and lung trial delays have created uncertainty, but successful completion in 12–18 months could reignite momentum. The long-term opportunity remains substantial, particularly OCS Kidney, but execution across new indications and Europe is increasingly critical to supporting TransMedics' valuation.

Seeking Alpha • Sep 18, 2026

2 Stocks Down 28% and 34% to Buy and Hold

TransMedics Group's investments are currently lowering margins, but they could eventually boost revenue and profits. SoFi Technologies is facing some near-term uncertainty, but the company's long-term prospects remain attractive.

The Motley Fool • Sep 15, 2026

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”).TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or.

Business Wire • Sep 14, 2026

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.

PRNewsWire • Sep 10, 2026

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026